List of Excipients in API doravirine, islatravir
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing doravirine, islatravir
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | IDVYNSO | doravirine, islatravir | 0006-5092 | CALCIUM CARBONATE | |
| Merck Sharp & Dohme LLC | IDVYNSO | doravirine, islatravir | 0006-5092 | CARNAUBA WAX | |
| Merck Sharp & Dohme LLC | IDVYNSO | doravirine, islatravir | 0006-5092 | CELLULOSE, MICROCRYSTALLINE | |
| Merck Sharp & Dohme LLC | IDVYNSO | doravirine, islatravir | 0006-5092 | CROSCARMELLOSE SODIUM | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for doravirine, islatravir
Excipient focus: CALCIUM CARBONATE
doravirine, islatravir drug variants containing CALCIUM CARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing CALCIUM CARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CARNAUBA WAX
doravirine, islatravir drug variants containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
doravirine, islatravir drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
doravirine, islatravir drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
doravirine, islatravir drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
doravirine, islatravir drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
doravirine, islatravir drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE
doravirine, islatravir drug variants containing HYPROMELLOSE ACETATE SUCCINATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing HYPROMELLOSE ACETATE SUCCINATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
doravirine, islatravir drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
doravirine, islatravir drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
doravirine, islatravir drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
doravirine, islatravir drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | doravirine, islatravir | 0006-5092 |
| >Company | >Ingredient | >NDC |
doravirine, islatravir drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch